Two drugs that inhibit deoxyhypusine hydoxylase (DOHH) may show promise as potential treatments for cervical cancer, according to research from scientists at Rutgers New Jersey Medical School.
Cytological specimen showing cervical cancer specifically squamous cell carcinoma in the cervix. Tissue is stained with pap stain and magnified x200.
SOURCE: The Web site of the National Cancer Institute (http://www.cancer.gov).
Just in time for Cervical Awareness Month, January 2014, two drugs that inhibit deoxyhypusine hydoxylase (DOHH) may show promise as potential treatments for cervical cancer, according to research from scientists at Rutgers New Jersey Medical School. The DOHH enzyme is believed to be essential to the molecular chain of events that leads to cervical cancer.
Researchers performed lab experiments on cells derived from a cervical cancer and found that when DOHH is blocked, a protein known as eIF5A fails to mature. That, in turn, alters the expression of genes that without the medications, ciclopirox (an antifungal) and deferiprone (a blood treatment), would cause cancer cells to proliferate.
“Some gene products go down and others go up, because mature eIF5A has more than one biochemical action inside cells,” said Michael Mathews, PhD, senior member of the research team in a press release. “For cell proliferation, each drug’s dual action is like both easing off the accelerator and depressing the brake pedal.”
For Mathews and his colleague Hartmut Hanauske-Abel, this is the second success involving these two medications. In September, a research team they led published similar findings in the journalPLoS ONEabout HIVevidence that the same two drugs eradicated the virus from infected cells examined in lab cultures.
Both of these medications are approved by the Food and Drug Administration for indications other than HIV and cervical cancer, which may create a potential shortcut to approval for these new indications, if the drugs prove their worth.
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
April 29th 2024Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More